Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17231772 | 1.00 | P2RY12 (0.37) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL26050307 | 0.91 | PRMT6 (0.40) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL19519374 | 0.91 | P2RY12 (0.37) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL23547992 | 0.89 | PRMT6 (0.40) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL26050516 | 0.87 | P2RY12 (0.32) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL26050510 | 0.87 | P2RY12 (0.32) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL17283015 | 0.87 | P2RY12 (0.32) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL7206380 | 0.86 | PRMT6 (0.35) | P2RY12PRMT6 | |
| SCHEMBL5482091 | 0.85 | P2RY12 (0.37) | P2RY12PRMT6P2RY2P2RY1P2RY6 | |
| SCHEMBL7522626 | 0.85 | PRMT6 (0.34) | P2RY12PRMT6P2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4286519-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3137479-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180016293-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016294-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2018-01-18 | — | — | US | disclosed |
| US-9796747-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2017-10-24 | — | — | US | disclosed |
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-11-26 | — | — | US | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337314-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | P2RY12 1532/4885PRMT6 3127/4885P2RY2 1700/4885 |
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | P2RY12 1532/4885PRMT6 3127/4885P2RY2 1700/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | P2RY12 1500/4885PRMT6 2148/4885P2RY2 2572/4885 |
| US-20180016293-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | P2RY12 1532/4885PRMT6 3127/4885P2RY2 1700/4885 |
| US-20180016294-A1 | Oligonucleotide Compositions and Methods of Making the Same | RNGTT, NSUN2, POLN | P2RY12 1532/4885PRMT6 3127/4885P2RY2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.